LOXL1 and LOXL4 are epigenetically silenced and can inhibit Ras/extracellular signal-regulated kinase signaling pathway in human bladder cancer

Cancer Research

Volumn 67, Issue 9, 2007, Pages 4123-4129

  Wu, Guojun ^a,c   Guo, Zhongmin ^a,b   Chang, Xiaofei ^a   Myoung, Sook Kim ^a   Nagpal, Jatin K ^a   Liu, Junwei ^a   Maki, Joni M ^d   Kivirikko, Kari I ^d   Ethier, Stephen P ^c   Trink, Barry ^a,e   Sidransky, David ^a,e  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF OULU   (Finland)

^e Department of Otolaryngology Head and Neck Surgery   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOXL1 ENZYME; LOXL4 ENZYME; MITOGEN ACTIVATED PROTEIN KINASE; OXIDOREDUCTASE; RAS PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BLADDER CANCER; CONTROLLED STUDY; EPIGENETICS; GENE EXPRESSION; GENE IDENTIFICATION; GENE LOCATION; GENE MUTATION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; METHYLATION; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROMOTER REGION; SIGNAL TRANSDUCTION; SOMATIC CELL;

AMINO ACID OXIDOREDUCTASES; AZACITIDINE; CELL LINE, TUMOR; CYTOPLASM; DNA METHYLATION; EPIGENESIS, GENETIC; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; MAP KINASE SIGNALING SYSTEM; MUTATION; RAS PROTEINS; TUMOR STEM CELLS; URINARY BLADDER NEOPLASMS;

EID: 34249293694     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-0012     Document Type: Article

References (44)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001;51:15-36.
2. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999;49:33-64.
3. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999;80:827-41.
4. Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 2000;16:168-74.
5. Robertson KD, Jones PA. DNA methylation: past, present and future directions. Carcinogenesis 2000;21: 461-7.
6. Ushijima T. Detection and interpretation of altered methylation patterns in cancer cells. Nat Rev Cancer 2005;5:223-31.
7. Chan MW, Chan LW, Tang NL, et al. Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin Cancer Res 2002;8: 464-70.
8. Hoque MO, Begum S, Topaloglu O, et al. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J Natl Cancer Inst 2006;98: 996-1004.
9. Jeronimo C, Usadel H, Henrique R, et al. Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer. Urology 2002;60:1131-5.
10. Valenzuela MT, Galisteo R, Zuluaga A, et al. Assessing the use of p16(INK4a) promoter gene methylation in serum for detection of bladder cancer. Eur Urol 2002;42: 622-8; discussion 8-30.
11. Kawai J, Hirotsune S, Hirose K, Fushiki S, Watanabe S, Hayashizaki Y. Methylation profiles of genomic DNA of mouse developmental brain detected by restriction landmark genomic scanning (RLGS) method. Nucleic Acids Res 1993;21:5604-8.
12. Ushijima T, Morimura K, Hosoya Y, et al. Establishment of methylation-sensitive-representational difference analysis and isolation of hypo- and hypermethylated genomic fragments in mouse liver tumors. Proc Natl Acad Sci U S A 1997;94:2284-9.
13. Gonzalgo ML, Liang G, Spruck CH III, Zingg JM, Rideout WM III, Jones PA. Identification and characterization of differentially methylated regions of genomic DNA by methylation-sensitive arbitrarily primed PCR. Cancer Res 1997;57:594-9.
14. Huang TH, Laux DE, Hamlin BC, Tran P, Tran H, Lubahn DB. Identification of DNA methylation markers for human breast carcinomas using the methylation-sensitive restriction fingerprinting technique. Cancer Res 1997;57:1030-4.
15. Huang TH, Perry MR, Laux DE. Methylation profiling of CpG islands in human breast cancer cells. Hum Mol Genet 1999;8:459-70.
16. Shi H, Yan PS, Chen CM, et al. Expressed CpG island sequence tag microarray for dual screening of DNA hypermethylation and gene silencing in cancer cells. Cancer Res 2002;62:3214-20.
17. Kim MS, Yamashita K, Baek JH, et al. N-methyl-D-aspartate receptor type 2B is epigenetically inactivated and exhibits tumor-suppressive activity in human esophageal cancer. Cancer Res 2006;66:3409-18.
18. Yamashita K, Upadhyay S, Osada M, et al. Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell 2002;2:485-95.
19. Wu G, Sinclair C, Hinson S, Ingle JN, Roche PC, Couch FJ. Structural analysis of the 17q22-23 amplicon identifies several independent targets of amplification in breast cancer cell lines and tumors. Cancer Res 2001;61; 4951-5.
20. Contente S, Kenyon K, Rimoldi D, Friedman RM. Expression of gene rrg is associated with reversion of NIH 3T3 transformed by LTR-c-H-ras. Science 1990;249: 796-8.
21. Giampuzzi M, Botti G, Cilli M, et al. Down-regulation of lysyl oxidase-induced tumorigenic transformation in NRK-49F cells characterized by constitutive activation of ras proto-oncogene. J Biol Chem 2001;276:29226-32.
22. Krzyzosiak WJ, Shindo-Okada N, Teshima H, Nakajima K, Nishimura S. Isolation of genes specifically expressed in flat revertant cells derived from activated ras-transformed NIH 3T3 cells by treatment with azatyrosine. Proc Natl Acad Sci U S A 1992;89:4879-83.
23. Kagan HM, Li W. Lysyl oxidase: properties, specificity, and biological roles inside and outside of the cell. J Cell Biochem 2003;88:660-72.
24. Molnar J, Fong KS, He QP, et al. Structural and functional diversity of lysyl oxidase and the LOX-like proteins. Biochim Biophys Acta 2003;1647:220-4.
25. Li W, Nellaiappan K, Strassmaier T, Graham L, Thomas KM, Kagan HM. Localization and activity of lysyl oxidase within nuclei of fibrogenic cells. Proc Natl Acad Sci U S A 1997;94:12817-22.
26. Smith-Mungo LI, Kagan HM. Lysyl oxidase: properties, regulation and multiple functions in biology. Matrix Biol 1998;16:387-98.
27. Kaneda A, Wakazono K, Tsukamoto T, et al. Lysyl oxidase is a tumor suppressor gene inactivated by methylation and loss of heterozygosity in human gastric cancers. Cancer Res 2004;64:6410-5.
28. Xu J, Zheng SL, Komiya A, et al. Germ line mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet 2002;32:321-5.
29. Kirschmann DA, Seftor EA, Fong SF, et al. A molecular role for lysyl oxidase in breast cancer invasion. Cancer Res 2002;62:4478-83.
30. Akiri G, Sabo E, Dafni H, et al. Lysyl oxidase-related protein-I promotes tumor fibrosis and tumor progression in vivo. Cancer Res 2003;63:1657-66.
31. Frier JT, Bennewith KL, Nicolau M, et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 2006;440:1222-6.
32. Contente S, Kenyon K, Sriraman P, Subramanyan S, Friedman RM. Epigenetic inhibition of lysyl oxidase transcription after transformation by ras oncogene. Mol Cell Biochem 1999;194:79-91.
33. Rost T, Pyritz V, Rathcke IO, Gorogh T, Dunne AA, Werner JA. Reduction of LOX- and LOXL2-mRNA expression in head and neck squamous cell carcinomas. Anticancer Res 2003;23:1565-73.
34. Maki JM, Kivirikko KI. Cloning and characterization of a fourth human lysyl oxidase isoenzyme. Biochem J 2001;355:381-7.
35. Maki JM, Tikkanen H, Kivirikko KI. Cloning and characterization of a fifth human lysyl oxidase isoenzyme: the third member of the lysyl oxidase-related subfamily with four scavenger receptor cysteine-rich domains. Matrix Biol 2001;20:493-6.
36. Wu G, Osada M, Guo Z, et al. DeltaNp63α up-regulates the Hsp70 gene in human cancer. Cancer Res 2005;65:758-66.
37. Oxford G, Theodorescu D. The role of Ras superfamily proteins in bladder cancer progression. J Urol 2003; 170:1987-93.
38. Ratovitski E, Trink B, Sidransky D. p63 and p73: teammates or adversaries? Cancer Cell 2006;9:1-2.
39. Patturajan M, Nomoto S, Sommer M, et al. DeltaNp63 induces β-catenin nuclear accumulation and signaling. Cancer Cell 2002;1:369-79.
40. Yamaguchi K, Wu L, Caballero OL, et al. Frequent gain of the p40/p51/p63 gene locus in primary head and neck squamous cell carcinoma. Int J Cancer 2000;86: 684-9.
41. Hajnal A, Klemenz R, Schafer R. Up-regulation of lysyl oxidase in spontaneous revertants of H-ras-transformed rat fibroblasts. Cancer Res 1993;53:4670-5.
42. Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 2001;93:1062-74.
43. Katz ME, McCormick F. Signal transduction from multiple Ras effectors. Curr Opin Genet Dev 1997;7:75-9.
44. Shinohara N, Koyanagi T. Ras signal transduction in carcinogenesis and progression of bladder cancer: molecular target for treatment? Urol Res 2002;30:273-81.